GPER can also influence tumor sensitivity to drugs by regulating cellular metabolism [230, 242]
Here's how they compare: Semaglutide (GLP-1 agonist) Mechanism: Single-action GLP-1 receptor agonist FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: 15-20% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients starting their weight loss journey seeking proven, well-studied medication Tirzepatide (dual GIP/GLP-1 agonist) Mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effect FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: Up to 22% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients seeking more aggressive fat loss with dual-action metabolic support Retatrutide (triple agonist, not yet available) Mechanism: Targets GLP-1, GIP, and glucagon receptors FDA status: Not FDA-approved
Tirzepatide is a dual GIP and GLP-1 receptor agonist , meaning it activates receptors responsive to two different incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
Dawki w badaniach na zwierztach: W zdecydowanej wikszoci bada przedklinicznych dawki stosowane u szczurw wahaj si midzy 10 g/kg a 10 ng/kg masy ciaa, podawane dootrzewnowo lub doustnie
AJNR Am J Neuroradiol
Magruder, a third-year resident at Maimonides Health in Brooklyn, NY and lead author of one of the presented studies, with the approval of semaglutide for the treatment of obesity by the FDA in 2021, and the surrounding media attention, it was clear that this medication was going to explode in popularity
